Short-Term Anatomic Effect of Ranibizumab for Polypoidal Choroidal Vasculopathy

Abstract

Purpose

To assess the short-term anatomic effect of intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Methods

All patients had undergone a full ophthalmic examination. A monthly injection of ranibizumab was performed for 3 months. Indocyanine angiography (ICG) and optical coherence tomography (OCT) were performed 1 month after the third-month ranibizumab injection.

Results

Polyps disappeared on ICG angiography in 9 out of 13 lesions (69.2%). Retinal thickness diminished significantly on OCT (p=0.02). In our series we noticed a significant reduction of the percentage of patients presenting with subretinal fluid (p=0.02) and pigment epithelium detachment between the initial and final visits (0.016). In addition, we noticed that BCVA increased significantly (p 0.02).

Conclusions

Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.

Keywords

Polypoidal choroidal vasculopathy Ranibizumab Optical coherence tomography Indocyanine green angiography

Get full access to this article

View all access options for this article.

References

Yannuzzi

L.A.

, Wong

D.W.

, Sforzolini

B.S.

Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 1999; 117: 1503–10.

Matsuoka

, Ogata

, Otsuji

Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 2004; 88: 809–15.

Terasaki

, Miyake

, Nakamura

Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol 2002; 86: 321–7.

Gomi

, Sawa

, Sakaguchi

Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92: 70–3.

Chan

W.M.

, Lam

D.S.

, Lai

T.Y.

Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111: 1576–84.

Mordenti

, Cuthbertson

R.A.

, Ferrara

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27: 536–44.